Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor-Reference-Cited by-同舟云学术

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor

Published:2017-02-18 Issue:5 Volume:15 Page:858-867
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Gerrits A. J.¹,Jakubowski J. A.²,Sugidachi A.³,Michelson A. D.¹,Frelinger A. L.¹

Affiliation:

1. Center for Platelet Research Studies; Division of Hematology/Oncology; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Boston MA USA

2. Lilly Research Laboratories; Eli Lilly and Company; Indianapolis IN USA

3. Biological Research Laboratories; Daiichi Sankyo Co., Ltd.; Tokyo Japan

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13627/fullpdf

Reference24 articles.

1. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis;Springthorpe;Bioorg Med Chem Lett,2007

2. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

3. Prasugrel versus clopidogrel in patients with acute coronary syndromes;Wiviott;N Engl J Med,2007

4. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study;Gurbel;Circulation,2009

5. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects;Teng;Eur J Clin Pharmacol,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ticagrelor inverse agonist activity at the P2Y₁₂ receptor is non‐reversible versus its endogenous agonist adenosine 5´‐diphosphate;British Journal of Pharmacology;2023-09

2. Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist;TH Open;2021-07

3. 60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study;Thrombosis Research;2020-06

4. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR);Platelets;2020-02-23

5. Flow Cytometry;Platelets;2019